While many of us procrastinate when it comes to our health, studies show men tend to resist medical care more than women. This June, as we celebrate Men’s Health Month,
/PRNewswire/ Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a clinical-stage biopharmaceutical company focused on repurposing.
US FDA Grants Fast Track Designation for Paradigm’s Phase 3 Osteoarthritis ProgramFDA Fast Track Designation for Pentosan Polysulfate Sodium (Zilosul™/PPS) offers pathways to expedite development of Paradigm’s osteoarthritis clinicalFDA Fast Track acknowledges osteoarthritis as a serious disease wi.
Approval demonstrates the potential of Zilosul™ to address an unmet medical need in OA which effects more than 72 million people in the US, EU5, and Canada KEY.